Xiaoli Meng
- Pharmacology top 1%
- Molecular Biology
- Pharmacology top 0.5%
- Immunology top 10%
- Organic Chemistry top 10%
- Co-authors
- Dean J. NaisbittAndrew V. StachulskiRosalind E. JenkinsMunir PirmohamedJames L. MaggsJ. WaddingtonPaul WhitakerArun Tailor
- Topics
- Drug-Induced Adverse Reactions (38 papers)Drug-Induced Hepatotoxicity and Protection (16 papers)Pharmacogenetics and Drug Metabolism (15 papers)
- Cited by
- PharmacologyToxicology
- Journals
- The LancetNature CommunicationsSHILAP Revista de lepidopterología
- Partner nations
- United KingdomUnited StatesChina
In The Last Decade
Xiaoli Meng
95 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 153
- Pharmacology 812
- Molecular Biology 444
- Pharmacology 440
- Immunology 306
- Organic Chemistry 239
Countries citing papers authored by Xiaoli Meng
This map shows the geographic impact of Xiaoli Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoli Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoli Meng more than expected).
Fields of papers citing papers by Xiaoli Meng
This network shows the impact of papers produced by Xiaoli Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoli Meng. The network helps show where Xiaoli Meng may publish in the future.
Co-authorship network of co-authors of Xiaoli Meng
This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoli Meng. A scholar is included among the top collaborators of Xiaoli Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoli Meng. Xiaoli Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 0 | |
| 6 | 2 | |
| 7 | 0 | |
| 8 | 3 | |
| 9 | 0 | |
| 10 | 3 | |
| 11 | 27 | |
| 12 | 16 | |
| 13 | 178 | |
| 14 | 13 | |
| 15 | 7 | |
| 16 | 11 | |
| 17 | 4 | |
| 18 | 50 | |
| 19 | A new novel mutation in FBN1 causes autosomal dominant Marfan syndrome in a Chinese family. | 21 |
| 20 | 2 |
About Xiaoli Meng
Xiaoli Meng is a scholar working on Pharmacology, Pharmacology and Immunology, having authored 108 papers that have together received 2.1k indexed citations. Recurring topics across this work include Drug-Induced Adverse Reactions (38 papers), Drug-Induced Hepatotoxicity and Protection (16 papers) and Pharmacogenetics and Drug Metabolism (15 papers). The work is most often cited by research in Pharmacology (440 citations), Pharmacology (812 citations) and Toxicology (102 citations). Xiaoli Meng has collaborated with scholars based in United Kingdom, United States and China. Frequent co-authors include Dean J. Naisbitt, Andrew V. Stachulski, Rosalind E. Jenkins, Munir Pirmohamed, James L. Maggs, J. Waddington, Paul Whitaker, Arun Tailor, B. Kevin Park and Neil French. Their work appears in journals such as The Lancet, Nature Communications and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.